Aadi Bioscience, Inc. announced that the Board removed Dr. Hehenberger as a member of the Audit Committee, and appointed Caley Castelein, M.D., a member of the Board who meets all audit committee independence and other eligibility requirements identified in Nasdaq Listing Rule 5605(c)(2)(A), to serve as a member of the Audit Committee, such that the Audit Committee consists of Emma Reeve, as chair, Richard Maroun and Caley Castelein, M.D. Dr. Castelein previously served as a member of the Audit Committee from March 2017 to September 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.9 USD | +3.26% | 0.00% | -5.94% |
Mar. 13 | Transcript : Aadi Bioscience, Inc., Q4 2023 Earnings Call, Mar 13, 2024 | |
Mar. 13 | Earnings Flash (AADI) AADI BIOSCIENCE Posts Q4 Revenue $6.3M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.94% | 46.65M | |
-2.68% | 85.68B | |
+5.53% | 41.4B | |
-24.99% | 28.22B | |
+55.20% | 24.64B | |
-7.19% | 16.98B | |
-34.20% | 13.29B | |
-17.31% | 11.66B | |
-11.43% | 11.65B | |
-0.82% | 8.18B |
- Stock Market
- Equities
- AADI Stock
- News Aadi Bioscience, Inc.
- Aadi Bioscience, Inc. Announces Management Changes